Public Employees Retirement Association of Colorado Sells 12,895 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Public Employees Retirement Association of Colorado lessened its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 309,070 shares of the medical research company's stock after selling 12,895 shares during the period. Public Employees Retirement Association of Colorado owned approximately 0.17% of IQVIA worth $60,735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $33,000. GKV Capital Management Co. Inc. purchased a new stake in IQVIA during the 4th quarter worth $39,000. Lee Danner & Bass Inc. purchased a new position in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IQV. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Barclays reiterated an "equal weight" rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Stock Up 1.1 %

NYSE:IQV traded up $1.65 during trading hours on Wednesday, hitting $155.10. 2,232,397 shares of the company's stock traded hands, compared to its average volume of 1,431,923. The firm has a market cap of $27.35 billion, a P/E ratio of 20.68, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock's fifty day moving average price is $169.86 and its two-hundred day moving average price is $192.72.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.